Latest Innovation News

Premier1 Lithium's latest quarterly report reveals multiple high-grade gold assay results at its Yalgoo Project and a successful $1.5 million capital raise, setting the stage for imminent drilling activities.

Orbital Corporation Ltd reports a strong quarterly update with 29 engines delivered, a debt-free balance sheet, and significant R&D grant funding supporting new engine development.

EVE Health Group has completed the sale of its Robyndale tea tree property and relaunched its postbiotic concentrate range, signaling a strategic shift towards innovation and growth in the Australian market.

DXN Limited reported a robust 58.1% revenue increase to $4.8 million in Q2 FY25, underpinned by strategic capital raising and new product innovation targeting AI infrastructure. The company is advancing key mining and telecom projects while streamlining operations to support its ambitious $16 million revenue guidance for FY25.

BlinkLab has launched its pivotal FDA registrational study for its AI-driven autism diagnostic app, BlinkLab Dx 1, following positive FDA feedback and promising preliminary results.

Impact Minerals Limited reported its December 2024 quarterly cash flow, revealing ongoing exploration expenditures and a significant $2.87 million grant to commercialise its High Purity Alumina process at Lake Hope.

Firebird Metals Limited has secured preliminary design approval for its battery-grade manganese sulphate plant in China and forged a strategic partnership to develop LMFP cathode materials, marking significant progress in its EV battery ambitions.

Bluechiip Limited remains in ASX suspension as it finalises its 2024 audited accounts, while its ongoing Strategic Review and BioLife deal set the stage for a pivotal 2025 focused on revenue growth and cash-flow break-even.

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.

Cycliq Group Ltd reports a robust Q2 FY2025 with a 15% rise in cash receipts to $1.92 million and strategic leadership appointments aimed at accelerating growth.

Cycliq Group Limited reported a robust net operating cash flow of $964,000 for the December 2024 quarter, bolstered by government grants and disciplined cost management. The company ended the period with a healthy cash balance of $1.12 million, signaling improved liquidity.